Wegovy Benefits Heart Disease Patients Regardless of Frailty
(MedPage Today) -- Frailty did not appear to prevent adults with cardiovascular disease and overweight or obesity from reaping the benefits of semaglutide (Wegovy), a secondary analysis of SELECT trial data indicated. By week 104, semaglutide...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.